Overview Dividends

(SMMT) Summit Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86627T1088

Antibody, Immunotherapy, Oncology, Clinical

Biotechnology
Market Cap in USD: 13,675m
IPO / Inception: 2015-03-05
Return 12m vs S&P 500: -20.2%

Dividends

Currently no dividends paid
Risk via 10d forecast
Volatility 116%
Value at Risk 5%th 155%
Relative Tail Risk -18.63%
Reward TTM
Sharpe Ratio 0.39
Alpha -22.53
CAGR/Max DD 0.85
Character TTM
Hurst Exponent 0.343
Beta 1.586
Beta Downside 0.306
Drawdowns 3y
Max DD 75.60%
Mean DD 41.03%
Median DD 40.51%

Description: SMMT Summit Therapeutics October 30, 2025

Summit Therapeutics PLC (NASDAQ:SMMT) is a U.S.-based biopharma focused on developing “patient-friendly” medicines, with its flagship candidate ivonescimab-a bispecific antibody that simultaneously blocks PD-1 and anti-angiogenesis pathways-currently in Phase III trials for non-small cell lung cancer (NSCLC). Founded in 2003 and headquartered in Miami, Florida, the company trades as common stock under the ticker SMMT in the Biotechnology sub-industry.

Key metrics that investors watch include the company’s cash runway of roughly $120 million (Q2 2024), which should fund operations into late 2025 assuming current burn rates, and a net loss of $45 million for the most recent twelve-month period, reflecting heavy R&D spend. The NSCLC market is projected to exceed $15 billion by 2028, while bispecific antibodies have seen a 35 % CAGR over the past three years, indicating strong secular tailwinds for ivonescimab’s therapeutic class.

If you’re looking to deepen your analysis, a quick look at Summit’s upcoming Phase III data release schedule and its partnership pipeline on ValueRay could help you gauge near-term catalysts and valuation sensitivity.

Piotroski VR‑10 (Strict, 0-10) 0.5

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)
FCFTA -1.14 (>2.0%) and ΔFCFTA -91.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -1.14 (>3.0%) and CFO -297.9m > Net Income -587.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (744.4m) change vs 12m ago 2.45% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.0% (prev -0.05%; Δ 0.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -39.5k (EBITDA TTM -355.8m / Interest Expense TTM 9000 ) >= 6 (WARN >= 3)

Altman Z'' -58.91

(A) 0.69 = (Total Current Assets 246.5m - Total Current Liabilities 64.9m) / Total Assets 261.7m
(B) -7.93 = Retained Earnings (Balance) -2.07b / Total Assets 261.7m
warn (B) unusual magnitude: -7.93 — check mapping/units
(C) -0.93 = EBIT TTM -355.8m / Avg Total Assets 382.3m
(D) -29.87 = Book Value of Equity -2.07b / Total Liabilities 69.5m
Total Rating: -58.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 43.18

1. Piotroski 0.50pt
2. FCF Yield -2.22%
3. FCF Margin data missing
4. Debt/Equity 0.04
5. Debt/Ebitda 0.27
7. RoE -210.3%
8. Rev. Trend -63.90%
9. EPS Trend 22.83%

What is the price of SMMT shares?

As of December 10, 2025, the stock is trading at USD 17.02 with a total of 3,899,728 shares traded.
Over the past week, the price has changed by -1.33%, over one month by -6.99%, over three months by -9.59% and over the past year by -8.79%.

Is SMMT a buy, sell or hold?

Summit Therapeutics has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy SMMT.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SMMT price?

Issuer Target Up/Down from current
Wallstreet Target Price 32.4 90.1%
Analysts Target Price 32.4 90.1%
ValueRay Target Price 20.1 18.3%

SMMT Fundamental Data Overview December 05, 2025

Market Cap USD = 13.68b (13.68b USD * 1.0 USD.USD)
P/S = 753.9008
P/B = 71.1287
Beta = -1.547
Revenue TTM = 0.0 USD
EBIT TTM = -355.8m USD
EBITDA TTM = -355.8m USD
Long Term Debt = 5.43m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.77m USD (from shortTermDebt, last fiscal year)
Debt = 7.22m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -97.6m USD (from netDebt column, last fiscal year)
Enterprise Value = 13.44b USD (13.68b + Debt 7.22m - CCE 238.6m)
Interest Coverage Ratio = -39.5k (Ebit TTM -355.8m / Interest Expense TTM 9000 )
FCF Yield = -2.22% (FCF TTM -298.5m / Enterprise Value 13.44b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 51.37 (set to none) (Enterprise Value 13.44b / Total Assets 261.7m)
Interest Expense / Debt = 0.12% (Interest Expense 9000 / Debt 7.22m)
Taxrate = 0.14% (-313.0k / -221.3m)
NOPAT = -355.3m (EBIT -355.8m * (1 - 0.14%)) [loss with tax shield]
Current Ratio = 3.80 (Total Current Assets 246.5m / Total Current Liabilities 64.9m)
Debt / Equity = 0.04 (Debt 7.22m / totalStockholderEquity, last quarter 192.3m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -97.6m / EBITDA -355.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -97.6m / FCF TTM -298.5m)
Total Stockholder Equity = 279.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -224.5% (out of range, set to none)
RoE = -210.3% (Net Income TTM -587.7m / Total Stockholder Equity 279.4m)
RoCE = -124.9% (out of range, set to none) (EBIT -355.8m / Capital Employed (Equity 279.4m + L.T.Debt 5.43m))
RoIC = -119.9% (out of range, set to none) (NOPAT -355.3m / Invested Capital 296.2m)
WACC = 11.85% (E(13.68b)/V(13.68b) * Re(11.86%) + D(7.22m)/V(13.68b) * Rd(0.12%) * (1-Tc(0.00)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.00%
Fair Price DCF = unknown (Cash Flow -298.5m)
EPS Correlation: 22.83 | EPS CAGR: 1.10% | SUE: -4.0 | # QB: 0
Revenue Correlation: -63.90 | Revenue CAGR: -16.48% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.139 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.74 | Chg30d=-0.058 | Revisions Net=-7 | Growth EPS=+3.0% | Growth Revenue=-96.7%

Additional Sources for SMMT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle